Skip to content

Effect of Chaihuang Qingyi Huoxue Granules on Intestinal Dysfunction in Patients with Acute Pancreatitis: A Dual-Center, Double-Blind, Randomized Controlled Clinical Trial

Effect of Chaihuang Qingyi Huoxue Granules on Intestinal Dysfunction in Patients with Acute Pancreatitis: A Dual-Center, Double-Blind, Randomized Controlled Clinical Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025002067
Enrollment
Unknown
Registered
2025-10-28
Start date
2025-11-01
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute pancreatitis

Interventions

Sponsors

The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for Mild Acute Pancreatitis (MAP) or Moderately Severe Acute Pancreatitis (MSAP) as outlined in the "Chinese Guidelines for the Diagnosis and Treatment of Acute Pancreatitis (2021)." 2. Meet the diagnostic criteria for "Damp-Heat Binding Syndrome" as specified in the "Expert Consensus on the Diagnosis and Treatment of Acute Pancreatitis in Traditional Chinese Medicine (2023)." 3. Gastrointestinal Symptom Rating Scale (GSRS) score is = 1 point. 4. Age between 18 and 65 years old inclusive with no gender restrictions. 5. Willing to participate in this study and sign or have a legal representative sign the Informed Consent Form. 6. Agree to take effective contraceptive measures during the trial period.

Exclusion criteria

Exclusion criteria: 1. Patients who have already reached SAP. 2. Those treated with Chinese patent medicines after onset. 3. Individuals with known severe cardiovascular, respiratory, renal, hepatic, or hematologic disorders, severe immunodeficiency, malignant tumors, epilepsy, or other similarly serious diseases. 4. Use of probiotics, corticosteroids, or immunosuppressive drugs within the past month. 5. Presence of clear intestinal ischemia or obstruction, severe abdominal distension or abdominal compartment syndrome, active gastrointestinal bleeding, high gastrointestinal fistula without a satisfactory enteral feeding tube, or any other condition that would prevent administration of Chinese medicines or enteral nutrition via the gastrointestinal tract. 6. Pregnant or lactating women. 7. Anyone with a known hypersensitivity to any component of the investigational product or its excipients. 8. Patients currently enrolled in, or who have participated in, another clinical drug trial within the past 4 weeks. 9. Individuals with a suspected or confirmed history of alcohol or drug abuse. 10. Any other circumstance that, in the investigator's opinion, could reduce the likelihood of successful enrollment or complicate follow-up (e.g., frequent job-related relocation).

Design outcomes

Primary

MeasureTime frame
Gastrointestinal Function Recovery Time;

Secondary

MeasureTime frame
Traditional Chinese Medicine (TCM) syndromes score.;Diamine Oxidase;D-Lactic Acid;Systemic Inflammatory Response Score;Gastrointestinal Function Score;gut microbiota;Serum Endotoxin;Procalcitonin;Inflammatory Factors;

Countries

China

Contacts

Public ContactLi Li

Southwest University of Medical Sciences Affiliated Traditional Chinese Medicine Hospital

13795749205@163.com+86 13795749205

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026